Seer (SEER) AI Stock Analysis

• Market Cap: $116.06M
• Dividend Yield: N/A
• Average Volume (3M): 149.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.35
• Revenue Growth: 12.13%
• EPS Growth: -8.23%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 52,294,370
• 10 Day Avg. Volume: 194,678
• 30 Day Avg. Volume: 149,900
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.52
• Enterprise Value/Revenue: -3.76
• Enterprise Value/Gross Profit: -7.59
• Enterprise Value/Ebitda: 0.74
• 1Y Price Target: $2.00
• Price Target Upside: -2.91% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 49 Neutral
• Price Target: $2.00 ▼(-2.91% Downside)

Seer's overall stock score is primarily influenced by its financial performance and earnings call insights. While the company shows promising revenue growth and strategic initiatives, ongoing profitability and cash flow challenges weigh heavily. The technical analysis and valuation further reflect a cautious outlook, with the stock lacking strong momentum and facing valuation concerns due to its unprofitability.

Positive Factors

Revenue Growth

Strong revenue growth indicates increasing demand for Seer's proteomic platforms, suggesting a robust market position and potential for continued expansion.

Strategic Partnerships

The partnership with Thermo Fisher enhances Seer's commercial reach, potentially accelerating adoption of its products and supporting long-term growth.

Strong Balance Sheet

A strong balance sheet with significant cash reserves provides financial stability and flexibility to invest in growth opportunities and navigate economic challenges.

Negative Factors

Profitability Challenges

Ongoing net losses highlight profitability challenges, which could hinder Seer's ability to reinvest in R&D and limit long-term financial sustainability.

Cash Flow Issues

Negative free cash flow indicates operational cash flow challenges, potentially impacting Seer's ability to fund operations and invest in future growth.

Capital Expenditure Constraints

CapEx constraints and longer sales cycles could delay expansion and adoption of new technologies, impacting Seer's growth trajectory and competitive position.

Seer Business Overview & Revenue Model

Company Description

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

How the Company Makes Money

Seer generates revenue primarily through the sale of its proteomic analysis platforms and related consumables to research institutions and pharmaceutical companies. Additionally, the company may earn revenue through service contracts where it conducts custom proteomic analyses for clients. Key partnerships with academic institutions and collaborations with pharmaceutical companies enhance its market presence and provide opportunities for joint research projects, which can also contribute to its earnings. Furthermore, grants and funding from governmental and private entities aimed at advancing proteomic research can serve as additional revenue sources.

Seer Financial Statement Overview

Summary

Seer shows revenue growth and a strong gross profit margin, but faces significant profitability challenges with negative net income and margins. The balance sheet is stable with low leverage, yet the company struggles to generate positive returns on equity. Cash flow improvements are noted, but negative operating cash flows indicate ongoing financial pressures.

Income Statement

Seer shows a modest revenue growth rate of 6.45% in the TTM, indicating some positive momentum. However, the company is struggling with profitability, as evidenced by a negative net profit margin of -5.11% and negative EBIT and EBITDA margins. The gross profit margin is relatively healthy at 49.51%, suggesting efficient cost management at the gross level, but high operating expenses are impacting overall profitability.

Balance Sheet

Seer maintains a low debt-to-equity ratio of 0.086, indicating conservative leverage and financial stability. However, the return on equity is negative at -25.93%, reflecting challenges in generating returns for shareholders. The equity ratio is strong, suggesting a solid capital structure, but the negative ROE highlights profitability issues.

Cash Flow

The company has a positive free cash flow growth rate of 7.88% in the TTM, which is a positive sign. However, both operating and free cash flows are negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow generation is somewhat aligned with net income, but the negative operating cash flow coverage ratio highlights ongoing operational cash flow issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.15M	13.95M	15.18M	14.69M	6.39M	656.00K
Gross Profit	7.99M	6.83M	7.03M	6.74M	3.19M	656.00K
EBITDA	-81.60M	-93.92M	-97.89M	-93.29M	-68.59M	-31.17M
Net Income	-82.44M	-86.60M	-86.28M	-88.70M	-68.63M	-31.17M
Balance Sheet
Total Assets	322.49M	366.60M	436.27M	487.93M	539.14M	442.32M
Cash, Cash Equivalents and Short-Term Investments	209.83M	236.41M	316.22M	421.24M	400.07M	431.86M
Total Debt	24.83M	25.96M	28.26M	29.87M	23.32M	0.00
Total Liabilities	34.20M	39.03M	39.37M	40.94M	36.22M	10.71M
Stockholders Equity	288.29M	327.57M	396.90M	446.99M	502.92M	431.61M
Cash Flow
Free Cash Flow	-54.54M	-49.69M	-66.37M	-71.05M	-53.27M	-25.36M
Operating Cash Flow	-51.66M	-46.11M	-59.06M	-60.78M	-46.35M	-20.83M
Investing Cash Flow	74.26M	65.86M	37.90M	-122.72M	-170.88M	-34.56M
Financing Cash Flow	-16.62M	-11.49M	452.00K	3.89M	116.63M	371.49M

Seer Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEER, the sentiment is Positive. The current price of 2.06 is below the 20-day moving average (MA) of 2.06, below the 50-day MA of 2.10, and below the 200-day MA of 2.13, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.72 is Neutral, neither overbought nor oversold. The STOCH value of 77.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SEER.

Seer Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADCT	54 Neutral	365.62M	-2.07	77.89%	―	15.73%	38.73%
FDMT	52 Neutral	311.04M	-1.79	-31.51%	―	0.00%	0.00%
SEER	49 Neutral	$116.06M	―	-25.25%	―	12.13%	-8.23%
SLN	49 Neutral	236.64M	-3.00	-33.81%	―	-40.10%	-16.60%
VOR	33 Underperform	192.56M	-0.11	0.00%	―	0.00%	-686.13%
KLRS	28 Underperform	74.32M	-0.59	0.00%	―	0.00%	73.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Seer Corporate Events

Seer Appoints Isaac Ro to Board of Directors

On September 2, 2025, Seer, Inc. announced the appointment of Isaac Ro to its Board of Directors, where he will also serve as a member of the Audit Committee. Mr. Ro’s extensive experience in financial leadership and the healthcare sector is expected to help Seer achieve transformative growth and enhance its platform’s impact. His appointment resolves any potential non-compliance with Nasdaq Listing Rules, and he will receive compensation in line with Seer’s outside director compensation policy.

The most recent analyst rating on (SEER) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Seer stock, see the SEER Stock Forecast page.

Seer Faces Nasdaq Compliance Challenge After Annual Meeting

On July 7, 2025, Seer, Inc. informed Nasdaq that it would no longer comply with Nasdaq Listing Rule 5605(c)(2)(A) following its 2025 Annual Meeting of Stockholders. The company plans to utilize the cure period to address the composition of its Audit Committee to regain compliance. During the Annual Meeting, stockholders elected six directors and ratified Deloitte & Touche LLP as the independent accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (SEER) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Seer stock, see the SEER Stock Forecast page.